Amrita V Kamath

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
    Amrita V Kamath
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 61:365-76. 2008
  2. ncbi request reprint Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543, USA
    Cancer Chemother Pharmacol 56:145-53. 2005
  3. ncbi request reprint P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA
    Cancer Chemother Pharmacol 55:110-6. 2005
  4. ncbi request reprint Effect of fruit juices on the oral bioavailability of fexofenadine in rats
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, P O Box 4000, Princeton, New Jersey 08543, USA
    J Pharm Sci 94:233-9. 2005
  5. ncbi request reprint Multiple pathways are involved in the oral absorption of BMS-262084, a tryptase inhibitor, in rats: role of paracellular transport, binding to trypsin, and P-glycoprotein efflux
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, P O Box 4000, Princeton, New Jersey 08543, USA
    J Pharm Sci 94:1115-23. 2005
  6. doi request reprint Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
    Punit H Marathe
    Pharmaceutical Candidate Optimization, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Cancer Chemother Pharmacol 65:55-66. 2009
  7. ncbi request reprint Modulation of tight junctions does not predict oral absorption of hydrophilic compounds: use of Caco-2 and Calu-3 cells
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    Arch Pharm Res 30:1002-7. 2007
  8. ncbi request reprint Selective Itk inhibitors block T-cell activation and murine lung inflammation
    Tai an Lin
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Biochemistry 43:11056-62. 2004
  9. doi request reprint Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey
    Benjamin M Johnson
    Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA
    Drug Metab Dispos 36:2475-83. 2008
  10. ncbi request reprint Choline uptake in human intestinal Caco-2 cells is carrier-mediated
    Amrita V Kamath
    Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Amherst, NY 14260, USA
    J Nutr 133:2607-11. 2003

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
    Amrita V Kamath
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 61:365-76. 2008
    ..Possible mechanisms contributing to the incomplete oral bioavailability of dasatinib in animals were investigated...
  2. ncbi request reprint Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543, USA
    Cancer Chemother Pharmacol 56:145-53. 2005
    ..The in vitro and in vivo pharmacokinetics and oral bioavailability of BMS-310705 were investigated in mice, rats, and dogs. In addition, comparison of the pharmacokinetics of BMS-310705 using various formulations was conducted in rats...
  3. ncbi request reprint P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA
    Cancer Chemother Pharmacol 55:110-6. 2005
    ..The oral bioavailability of BMS-387032 has been found to be about 31% in rats. Absorption and first-pass metabolism were evaluated as possible reasons for the incomplete oral bioavailability in rats...
  4. ncbi request reprint Effect of fruit juices on the oral bioavailability of fexofenadine in rats
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, P O Box 4000, Princeton, New Jersey 08543, USA
    J Pharm Sci 94:233-9. 2005
    ..This fruit juice--drug interaction rat model may be useful in prediction of potential food--drug interactions in humans for drug candidates...
  5. ncbi request reprint Multiple pathways are involved in the oral absorption of BMS-262084, a tryptase inhibitor, in rats: role of paracellular transport, binding to trypsin, and P-glycoprotein efflux
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, P O Box 4000, Princeton, New Jersey 08543, USA
    J Pharm Sci 94:1115-23. 2005
    ..P-gp efflux may also play a role in influencing the absorption of BMS-262084. The intestinal dipeptide transporter system does not appear to be involved in the absorption of BMS-262084...
  6. doi request reprint Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
    Punit H Marathe
    Pharmaceutical Candidate Optimization, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Cancer Chemother Pharmacol 65:55-66. 2009
    ..In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts...
  7. ncbi request reprint Modulation of tight junctions does not predict oral absorption of hydrophilic compounds: use of Caco-2 and Calu-3 cells
    Amrita V Kamath
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    Arch Pharm Res 30:1002-7. 2007
    ....
  8. ncbi request reprint Selective Itk inhibitors block T-cell activation and murine lung inflammation
    Tai an Lin
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Biochemistry 43:11056-62. 2004
    ..Our findings represent the first description of selective inhibitors to probe human Itk function and its associated pathway, and support the hypothesis that Itk is a therapeutic target for immunosuppressive and inflammatory diseases...
  9. doi request reprint Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey
    Benjamin M Johnson
    Pharmaceutical Candidate Optimization, Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA
    Drug Metab Dispos 36:2475-83. 2008
    ....
  10. ncbi request reprint Choline uptake in human intestinal Caco-2 cells is carrier-mediated
    Amrita V Kamath
    Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Amherst, NY 14260, USA
    J Nutr 133:2607-11. 2003
    ..P-glycoprotein substrates may inhibit choline uptake through specific or nonspecific interactions with the choline transporter...